Mind the gap - the benefits of modern biologic treatment
Professor Piaserico gives a detailed explanation of the role of the different cytokines in the pathogenesis of psoriasis and why targeting IL-23 might be more favourable than targeting IL-17. He also discusses the most important drug characteristics for patients with psoriasis and the need to consider what happens when stopping treatment.
The Psoriasis Management, Psoriasis Treatment and Psoriasis Guidelines content has been developed by EPG Health for Medthority. This content has been developed independently of the sponsor Almirall S.A, who have had no editorial input into the content. EPG Health received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.
The Expert Opinion and PsoMOT content has been developed by EPG Health for Medthority in collaboration with the sponsor Almirall S.A., utilising content from their Almirall funded symposium at EADV 2021 and PsoMOT meeting in November 2019.